NCT04438382 2026-04-02
Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis
Eastern Cooperative Oncology Group
Phase 2 Terminated
Clinical Trials
9 trialsNCT04305145 2026-01-29
Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT05034536 2026-01-08
PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT06646016 2025-12-26
EPIC
Therakos LLC
Phase 2 Withdrawn
NCT06136546 2025-05-07
Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab
Massachusetts General Hospital
Phase 2 Recruiting
NCT00112749 2020-07-31
Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Terminated
NCT02763761 2018-10-09
An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo
Bristol-Myers Squibb
Phase 2 Withdrawn
NCT02457585 2017-05-15
Clinical Study of Anti-tumor Necrosis Factor Therapy in Patients With Takayasu Arteritis
Seoul National University Hospital
Phase 2 Unknown
NCT00060502 2011-05-17
A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Pancreatic Cancer Related Cachexia
Centocor, Inc.
Phase 2 Completed